Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BNOS 2022 | Current and future strategies in glioblastoma therapy

Igor Vivanco, PhD, King’s College London, London, UK, comments on novel developments in the treatment landscape for glioblastoma. The current standard of care for BRAF-mutant gliomas, which constitute a small number of total patients with glioma, is BRAF and MEK inhibitors. As drug resistance can occur when using targeted therapies, there is a need to elucidate strategies to overcome resistance. Immunotherapies such as checkpoint inhibitors has additionally been assessed in glioblastoma and may show promise as a debulking regimen in conjunction with existing therapies. This interview took place at the British Neuro-Oncology Society (BNOS) Annual Meeting 2022.

Disclosures

Dr Vivanco reports has received consulting honoraria from Abbvie and Aadi, as well as research funding from Roche, Genmab, and Basilea.